Free Submission Public Relations &
Deutsch English

Prezista (HIV) - Forecast and Market Analysis to 2022

Global Prezista market: Latest market analysis presented

Print article Print article
2014-03-12 21:09:01 - Prezista (HIV) - Forecast and Market Analysis to 2022 - a new market research report on

Prezista (HIV) - Forecast and Market Analysis to 2022 - GlobalData has released its new PharmaPoint Drug Evaluation report, "Prezista (HIV) - Forecast and Market Analysis to 2022". Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through



the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.

Prezista (darunavir) is an HIV PI that is co-administered with AbbVies Norvir (ritonavir) in combination with other antiretroviral agents for the treatment of HIV-infected patients. Prezistas mechanism of action involves selectively inhibiting the cleavage of HIV gag-pol polyprotein, which prevents the formation of mature, infectious virus particles (Prezista prescribing information, 2012). Norvir is a modest inhibitor of the HIV protease, but it mainly acts as a pharmacokinetic enhancer of Prezista. Ritonavir increases the plasma levels of Prezista by inhibiting the cytochrome P450 enzyme CYP3A, which would otherwise decrease bioavailability and half-life of Prezista via metabolism (Prezista prescribing information, 2012).


- Overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Prezista including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Prezista for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HIV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Prezista performance
- Obtain sales forecast for Prezista from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Mike King
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact